The AF-specific effects of SGLT-2 inhibitors seem separate from their consistently reported CV protective properties; those derive from pleiotropic hemodynamic mechanisms, including effects on arterial stiffness, blood pressure, body weight, or heart failure (HF) risk, none of which directly relate to atrial remodeling [5]. The gene discussed is SLC5A2; the disease is heart failure.